Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$312.32 +1.2%	$274.47	$153.23 ▼ $317.54	$40.25B	0.22	932,639 shs	981,185 shs
BIIB Biogen	$126.54 0.0%	$124.33	$110.04 ▼ $238.00	$18.54B	0.14	1.43 million shs	2.33 million shs
INCY Incyte	$68.27 -0.8%	$62.97	$53.56 ▼ $83.95	$13.32B	0.67	2.05 million shs	1.74 million shs
REGN Regeneron Pharmaceuticals	$513.58 +0.9%	$559.88	$476.49 ▼ $1,211.20	$54.94B	0.31	884,759 shs	841,026 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-0.02%	+2.07%	+8.20%	+21.81%	+96.26%
BIIB Biogen	-3.42%	-6.59%	+0.77%	-10.51%	-44.11%
INCY Incyte	-3.38%	-1.80%	+8.69%	+14.04%	+9.76%
REGN Regeneron Pharmaceuticals	-2.64%	-2.80%	-14.38%	-24.32%	-51.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.1913 of 5 stars	2.4	5.0	0.0	4.3	2.8	2.5	0.6
BIIB Biogen	4.8316 of 5 stars	4.2	3.0	0.0	3.7	3.1	1.7	2.5
INCY Incyte	4.4972 of 5 stars	2.1	4.0	0.0	3.1	3.1	2.5	3.1
REGN Regeneron Pharmaceuticals	4.8571 of 5 stars	4.4	4.0	1.7	2.3	2.7	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.77	Moderate Buy	$319.58	2.33% Upside
BIIB Biogen	2.38	Hold	$188.19	48.72% Upside
INCY Incyte	2.22	Hold	$74.53	9.17% Upside
REGN Regeneron Pharmaceuticals	2.85	Moderate Buy	$836.48	62.87% Upside

Current Analyst Ratings Breakdown

Latest BIIB, REGN, ALNY, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	INCY Incyte	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$75.00 ➝ $107.00
6/12/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $338.00
6/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$115.00
6/12/2025	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$121.00
6/12/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/9/2025	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$950.00 ➝ $800.00
6/5/2025	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$633.00 ➝ $560.00
6/3/2025	INCY Incyte	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/3/2025	INCY Incyte	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$61.00
6/2/2025	REGN Regeneron Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$700.00 ➝ $650.00
6/2/2025	REGN Regeneron Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$800.00 ➝ $600.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	18.11	N/A	N/A	$0.52 per share	600.62
BIIB Biogen	$9.68B	1.92	$23.09 per share	5.48	$114.71 per share	1.10
INCY Incyte	$4.24B	3.12	$0.55 per share	124.29	$17.90 per share	3.81
REGN Regeneron Pharmaceuticals	$14.20B	3.90	$46.10 per share	11.14	$268.50 per share	1.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	350.92	N/A	-11.49%	-510.31%	-6.48%	7/30/2025 (Estimated)
BIIB Biogen	$1.63B	$10.13	12.49	7.66	1.00	15.07%	14.03%	8.32%	7/30/2025 (Estimated)
INCY Incyte	$32.62M	$0.32	213.35	10.44	0.58	0.48%	2.77%	1.77%	7/29/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$39.28	13.07	13.51	1.86	31.94%	15.27%	11.93%	7/30/2025 (Estimated)

Latest BIIB, REGN, ALNY, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
4/29/2025	Q1 2025	INCY Incyte	$1.01	$1.16	+$0.15	$0.80	$996.17 million	$1.05 billion
4/29/2025	Q1 2025	REGN Regeneron Pharmaceuticals	$8.83	$8.22	-$0.61	$7.27	$3.40 billion	$3.03 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.52	0.69%	N/A	8.96%	N/A

Latest BIIB, REGN, ALNY, and INCY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	8.88	3.04	2.98
BIIB Biogen	0.27	1.44	1.01
INCY Incyte	0.01	2.04	2.00
REGN Regeneron Pharmaceuticals	0.09	4.93	4.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
INCY Incyte	96.97%
REGN Regeneron Pharmaceuticals	83.31%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.50%
BIIB Biogen	0.18%
INCY Incyte	17.80%
REGN Regeneron Pharmaceuticals	7.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	130.39 million	128.43 million	Optionable
BIIB Biogen	7,605	146.53 million	146.26 million	Optionable
INCY Incyte	2,617	193.57 million	159.12 million	Optionable
REGN Regeneron Pharmaceuticals	15,106	107.96 million	100.39 million	Optionable

BIIB, REGN, ALNY, and INCY Headlines

Recent News About These Companies

Regeneron Pharmaceuticals (REGN) Announces Key Decisions from 2025 Annual Shareholders Meeting

June 19 at 12:29 AM | gurufocus.com

Grove Bank & Trust Has $514,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

June 18 at 4:32 AM | marketbeat.com

Exchange Traded Concepts LLC Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

June 18 at 3:58 AM | marketbeat.com

Regeneron is said to have declined a higher bid for 23andMe after Wojcicki's offer

June 17 at 4:08 PM | msn.com

PKO Investment Management Joint Stock Co Has $9.70 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

June 17 at 6:55 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Schaper Benz & Wise Investment Counsel Inc. WI

June 17 at 5:47 AM | marketbeat.com

Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer

June 16 at 5:23 PM | reuters.com

Anne Wojcicki overcomes Regeneron in 23andMe assets battle

June 16 at 1:11 PM | thepharmaletter.com

BDF Gestion Sells 580 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

June 16 at 7:05 AM | marketbeat.com

Warther Private Wealth LLC Sells 4,200 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

June 16 at 6:08 AM | marketbeat.com

Mn Services Vermogensbeheer B.V. Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

June 16 at 5:23 AM | marketbeat.com

Leerink Partnrs Has Pessimistic Outlook of REGN Q2 Earnings

June 16 at 1:20 AM | marketbeat.com

Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis

June 15 at 12:04 PM | msn.com

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

June 15 at 11:22 AM | globenewswire.com

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

June 15 at 11:21 AM | globenewswire.com

Asio Capital LLC Has $2.53 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

June 15 at 8:30 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Increased by Factory Mutual Insurance Co.

June 15 at 7:52 AM | marketbeat.com

Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Target Price at $836.48

June 15 at 2:49 AM | americanbankingnews.com

New England Research & Management Inc. Invests $384,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

June 14, 2025 | marketbeat.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Fifth Third Bancorp

June 14, 2025 | marketbeat.com

1,547 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Harbor Capital Advisors Inc.

June 14, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB, REGN, ALNY, and INCY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$312.32 +3.61 (+1.17%)

Closing price 04:00 PM Eastern

Extended Trading

$310.83 -1.49 (-0.48%)

As of 04:55 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$126.54 -0.02 (-0.02%)

Closing price 04:00 PM Eastern

Extended Trading

$126.50 -0.04 (-0.03%)

As of 07:11 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Incyte NASDAQ:INCY

$68.27 -0.54 (-0.78%)

Closing price 04:00 PM Eastern

Extended Trading

$67.68 -0.58 (-0.86%)

As of 07:11 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Regeneron Pharmaceuticals NASDAQ:REGN

$513.58 +4.72 (+0.93%)

Closing price 04:00 PM Eastern

Extended Trading

$512.50 -1.08 (-0.21%)

As of 07:59 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time